Neutral
Eli Lilly's stock price remains steady at $1,159.60 amid recent developments.
In the past 24 hours, Eli Lilly's stock price has remained unchanged at $1,159.60. Recent developments include the company's acquisition of Merida Biosciences for up to $2.88 billion, expanding its immunology pipeline, and the announcement of positive Phase 3b data for Taltz and Zepbound in treating psoriatic disease and obesity. Additionally, Lilly plans to participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026.
Key points
- Eli Lilly's stock price remains steady at $1,159.60.
- Eli Lilly acquires Merida Biosciences for up to $2.88 billion, enhancing its immunology pipeline.
- Positive Phase 3b data for Taltz and Zepbound in treating psoriatic disease and obesity.
- Eli Lilly to participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026.
Sources
- Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipelineProactive Investors · August 31, 2026
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesityPR Newswire · August 31, 2026
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare ConferenceStockTitan · September 1, 2026
AI-generated from public news sources. Not financial advice.
